证券代码：002432 证券简称：九安医疗 公告编号：2025-015 天津九安医疗电子股份有限公司 关于回购公司股份的进展公告 1、公司未在下列期间内回购公司股票： （1）自可能对公司股票交易价格产生重大影响的重大事项发生之日或者在 决策过程中，至依法披露之日内； （2）中国证监会和深圳证券交易所规定的其他情形。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9号—回购股份》等相关规定，公司在回购期间应当在每个月的前3个交易日内公 告截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 一、回购股份的具体情况 截至2025年3月31日，公司通过股份回购专用证券账户以集中竞价方式累计 回购公司股份数1,193,900股，占公司总股本的0.25%，最高成交价为42.17元/股， 最低成交价为41.64元/股，支付的总金额为人民币49,995,031.30元（不含交易费 用）。本次回购符合相关法律法规的要求，符合既定的回购股份方案。 二、其他说明 公司回购股份的时间、数量、价格及集中竞价交易的委托时间段均符合《深 圳证券交易所上市公司自律监管指引第9号—回购股份》及公司回购股份方案的 ...

4月1日，九安医疗今日收盘42.67元，上涨1.50%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到11.71倍，创19天以来新低，总市值201.87亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均46.46倍，行业中值33.07倍，九安医疗排 名第28位。 截至2024年三季报，共有351家机构持仓九安医疗，其中基金350家、券商1家，合计持股数6577.57万 股，持股市值26.82亿元。 天津九安医疗电子股份有限公司专注家用医疗器械的研发、生产及销售以及云平台系统及服务,逐步转 型成为互联网+医疗解决方案提供商。公司主要产品为Health系列产品、非自主品牌产品、传统硬件产 品、互联网医疗产品及服务、新零售业务。 最新一期业绩显示，2024年三季报，公司实现营业收入20.92亿元，同比-23.79%；净利润13.69亿元，同 比52.63%，销售毛利率71.68%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)28九安医疗11.7116.131.05201.87亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1 ...

Core Points - The Shanghai Composite Index decreased by 0.46%, while the CSI All-Share Healthcare Equipment and Services Index fell by 1.41%, closing at 13712.26 points with a trading volume of 15.283 billion [1] - Over the past month, the CSI All-Share Healthcare Equipment and Services Index has declined by 0.80%, and by 1.23% over the last three months, but has increased by 1.60% year-to-date [1] - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these securities, with a base date of December 31, 2004, set at 1000.0 points [1] Index Holdings - The top ten weighted companies in the CSI All-Share Healthcare Equipment and Services Index are: Mindray Medical (9.67%), Aier Eye Hospital (8.27%), United Imaging (6.71%), Aimeike (3.63%), New Industry (3.05%), Huatai Medical (3.02%), Yuyue Medical (2.8%), Meinian Onehealth (2.36%), Jiuan Medical (2.2%), and Shandong Pharmaceutical Glass (2.07%) [1] - The market segments of the index holdings show that 61.63% are from the Shenzhen Stock Exchange and 38.37% from the Shanghai Stock Exchange [1] Industry Composition - The healthcare sector accounts for 100.00% of the index sample holdings [2] - The index sample is adjusted biannually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - Public funds tracking the healthcare sector include various funds such as Southern CSI All-Share Healthcare Equipment and Services Link A, Tianhong CSI All-Share Healthcare Equipment and Services ETF, and others [2]

证券代码：002432 证券简称：九安医疗 公告编号：2025-014 天津九安医疗电子股份有限公司 关于首次回购公司股份的公告 根据《深圳证券交易所上市公司自律监管指引第9号—回购股份》等相关规 定，公司应当在首次回购股份事实发生的次一交易日予以披露。现将公司首次回 购股份的情况公告如下： 1、公司未在下列期间内回购公司股票： 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 天津九安医疗电子股份有限公司（以下简称："公司"）于2025年3月26日 召开了第六届董事会第十九次会议，审议并通过了《关于公司回购股份方案的议 案》。本次回购资金来源为公司自有资金及回购专项贷资金，回购的资金总额不 低于2.5亿元人民币（含）且不超过5亿元人民币（含），回购股份的价格为不超 过人民币50元/股（含），具体回购数量以回购期限届满时实际回购的股份数量为 准。具体回购方案详见公司2025年3月27日在《证券时报》和巨潮资讯网 （http://www.cninfo.com.cn）披露的《关于回购公司股份方案暨取得股票回购专 项贷款承诺函的公告》（公告编号：202 ...

Core Viewpoint - The company plans to repurchase shares to enhance investor confidence and support its employee stock ownership plan, with a total repurchase amount between 250 million and 500 million RMB [2][3][11] Summary by Sections Repurchase Plan - The company intends to repurchase shares through centralized bidding in the secondary market, with a total fund of no less than 250 million RMB and no more than 500 million RMB [2][6] - The repurchase price will not exceed 50 RMB per share, potentially allowing for the repurchase of approximately 5 million to 10 million shares, representing about 1.06% to 2.11% of the total share capital [2][6][9] Purpose and Use of Repurchased Shares - The repurchased shares will be used for the employee stock ownership plan, aimed at aligning the interests of shareholders, the company, and employees, thereby promoting sustainable development [3][11] Funding Sources - The funding for the repurchase will come from the company's own funds and a special loan for share repurchase, with a commitment from a bank to provide up to 450 million RMB [6][7] Implementation Timeline - The repurchase will be executed within 12 months from the board's approval, with specific conditions for early termination or extension based on stock price movements and significant corporate events [7][9] Share Structure Changes - If the repurchase is fully executed, the share structure will change slightly, with the proportion of restricted shares increasing from 5.79% to 7.91% and unrestricted shares decreasing from 94.21% to 92.09% [8][10] Financial Impact - The total repurchase amount will represent approximately 2.04% of the company's total assets and 2.59% of net assets, indicating a manageable impact on the company's financial health [11]

回购报告书 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 重要内容提示： 1、天津九安医疗电子股份有限公司（以下简称"公司"）于2025年3月26日 召开第六届董事会第十九次会议，逐项审议并通过了《关于公司回购股份方案的 议案》。根据《公司章程》的规定，本次回购股份方案在董事会决策权限之内， 无需提交股东大会审议。 2、回购方案的主要内容： 证券代码：002432 证券简称：九安医疗 公告编号：2025-013 天津九安医疗电子股份有限公司 公司拟通过二级市场以集中竞价交易的方式回购公司部分社会公众股份（以 下简称"本次回购"），回购资金来源为公司自有资金及回购专项贷资金。本次回 购的资金总额不低于2.5亿元人民币（含）且不超过5亿元人民币（含），回购股 份的价格为不超过人民币50元/股（含）。若按回购资金总额下限和回购股份价格 上限进行测算，预计可回购股份数量约为5,000,000股，约占公司目前总股本的 1.06%；按回购资金总额上限和回购股份价格上限测算，预计可回购股份数量约 为10,000,000股，约占公司目前总股本的2.11%，具 ...

Core Viewpoint - The company has appointed Rongcheng Accounting Firm as the auditor for its 2024 financial statements and internal controls, following the approval of the board and shareholders [1][2]. Group 1: Appointment of Auditor - The company held its 17th board meeting on December 10, 2024, and the third extraordinary shareholders' meeting on December 26, 2024, where the appointment of Rongcheng as the auditing firm for 2024 was approved [1]. - The announcement regarding the appointment was disclosed on December 11, 2024, in the Securities Times and on the Giant Tide Information Network [1]. Group 2: Change of Signing Accountants - The signing accountants for the 2024 audit have changed; Yang Qihu is no longer serving due to work arrangement adjustments, and Ji Yuhong and Cui Shuai have been appointed as new signing accountants [2]. - The remaining signing accountant is Li Dongxin, who continues as the project partner [2]. Group 3: Background of New Signing Accountants - Ji Yuhong has been a certified public accountant since 2003 and has been involved in auditing listed companies since 1999, with experience at Rongcheng since 2008 [3]. - Cui Shuai became a certified public accountant in 2020 and has been involved in auditing listed companies since then, starting at Rongcheng in 2022 [3]. Group 4: Integrity and Independence - Both Ji Yuhong and Cui Shuai have no criminal penalties or administrative sanctions from regulatory bodies in the past three years [4]. - They also comply with the independence requirements set forth in the Code of Ethics for Chinese Certified Public Accountants [5]. Group 5: Impact of Changes - The transition of signing accountants has been orderly, and it is stated that the changes will not affect the audit of the company's 2024 financial statements and internal controls [6].

Core Viewpoint - Tianjin Jiuan Medical Electronics Co., Ltd. has announced a share repurchase plan, which was approved during the 19th meeting of the 6th Board of Directors held on March 26, 2025 [1]. Group 1: Share Repurchase Plan - The company has disclosed details regarding the share repurchase plan in a separate announcement dated March 27, 2025 [1]. - The announcement includes information about the top ten shareholders and their respective shareholding proportions as of the close of trading on March 26, 2025 [1]. Group 2: Top Ten Shareholders - The top ten shareholders include various employee stock plans and investment funds, with their shareholding numbers and proportions provided [2]. - The shareholding data combines both ordinary accounts and margin trading accounts, excluding shares held in the company's repurchase account [2]. Group 3: Top Ten Unrestricted Shareholders - Similar to the top ten shareholders, the top ten unrestricted shareholders' information is also detailed, including their shareholding numbers and proportions [2]. - The same methodology for calculating shareholding applies, combining ordinary and margin trading accounts while excluding repurchase account shares [2].

一、签字注册会计师变更情况 容诚作为公司 2024 年度财务报表和内部控制的审计机构，原委派李东昕（项 目合伙人）、杨七虎为签字注册会计师为公司提供审计服务。现因杨七虎工作安 排调整，不再担任公司签字注册会计师，容诚现委派纪玉红、崔帅帅作为签字注 册会计师，继续完成公司 2024 年度财务报表和内部控制审计相关工作。变更后， 公司 2024 年度财务报表和内部控制审计的签字注册会计师为李东昕（项目合伙 人）、纪玉红和崔帅帅。 二、变更后签字注册会计师基本情况 1.基本信息 纪玉红，2003 年成为中国注册会计师，1999 年开始从事上市公司审计业务， 2008 年开始在容诚会计师事务所执业，2024 年开始为公司提供审计服务；近三 年签署过 3 家以上上市公司审计报告。 证券代码：002432 证券简称：九安医疗 公告编号：2025-012 天津九安医疗电子股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 天津九安医疗电子股份有限公司（以下简称"公司"）于 2024 年 12 月 10 日 召开第六届董 ...

及前十名无限售条件股东持股情况的公告 本公司及董事会全体成员保证公告内容真实、准确和完整， 并对公告中的虚假记载、误导性陈述或者重大遗漏承担连带责任。 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年3月26日召开 第六届董事会第十九次会议，审议通过了《关于公司回购股份方案的议案》。具 体 内 容 详 见 公 司 于 2025 年 3 月 27 日 在 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《关于回购公司股份方案暨取得股票回购专 项贷款承诺函的公告》（公告编号：2025-010）。 根据《深圳证券交易所上市公司自律监管指引第9号—回购股份》等相关规 定，现将回购方案公告前一个交易日（即2025年3月26日）收盘后登记在册的前 十名股东和前十名无限售条件股东的名称、持股数量和持股比例情况公告如下： | 序号 | 股东名称 | 持股数量 （股） | 占公司最新总股 份比例（%） | | --- | --- | --- | --- | | 1 | 石河子三和股权投资合伙企业（有限合伙） | 116544519.00 | 24.63 | ...